SAN FRANCISCO -- (BUSINESS WIRE) -- David Jin, M.D., Ph.D., Chief Medical Officer, at BioTime Inc. (NYSE/AMEX: BTX) has been selected by ExecRank as a “Top Chief Medical Officer” for 2012. The rankings are the result of 2-years of research and feedback from evaluation committees and top Chief Medical Officers that yielded an algorithm for how to rank Medical Executives based on their performance in 24 key areas.
According to Adam Navrozally, Lead Analyst for the rankings division of ExecRank, “Dr. Jin has a long record of success in strategic research and development, while complying with increasingly strict regulatory standards. His strong record of success in both academic presentations and research publications makes him a strong asset to BioTime. He is highly regarded in his field, and amongst other Chief Medical Officers.”
According to Dr. Jin, “It is truly an honor to be elected by my peers, and recognized by ExecRank, as a Top Chief Medical Officer for 2012. I share this achievement with my colleagues at BioTime and our subsidiaries who support me and the corporation. The award has motivated me to continue to work toward achieving the best practices in the field of stem cell and regenerative medicine.”
For the complete rankings, please visit www.ExecRank.com.
About Dr. Jin
Dr. David Jin became the Chief Medical Office for BioTime Inc. as well as its two subsidiaries, namely BioTime Asia Limited and OncoCyte Corporation since 2010. Dr. Jin is a licensed physician in the U.S. who has over 15 years of diverse experience in clinical trials, strategic consulting, regulatory affairs, and biotechnology development. After graduating as class valedictorian with summa cum laude distinction from Massachusetts College of Pharmacy in 1992, Dr. Jin further obtained a combined M.D. and Ph.D. degrees from the State University of New York Downstate College of Medicine. He completed his clinical training in internal medicine, hematology, and oncology at New York-Presbyterian Hospital (the teaching hospital for Columbia and Cornell University School of Medicine), and subsequently became clinical and research faculty at Cornell. During his academic tenure, Dr. Jin has directed over 10 clinical trials at various R&D stages sponsored by major pharmaceutical companies. He has served as senior clinician-scientist at the Ansary Stem Cell Institute and published over 30 peer-reviewed research and clinical papers, some in prestigious journals including Nature, Nature Medicine, Cell, and PNAS. Dr. Jin has worked for the U.S. Food and Drug Administration as medical reviewer for oncology product development. Recently, Dr. Jin has been appointed by China’s Ministry of Health as external adviser and member of the evaluation committee for MOH’s Third Category Medical Treatment Technology (for regulation and standardization of stem cell therapy and cell-based immunotherapy), as well as adviser to the Chinese-UK “Dynasty Project” to establish an international collaborative zone for clinical medicine in Wuhan BioLake.